"La IPS CENTRO CIENTIFICO ASITENCIAL S.A.S ofrece servicios de salud de baja y mediana complejidad, orientados al fomento de la salud, la prevención primaria y secundaria, tratamiento y seguimiento de enfermedades crónicas no transmisibles, en el contexto de la conducción de estudios clínicos, bajo el rigor de los preceptos éticos y científicos de las Buenas Prácticas Clínicas."
Top Sponsors
Top Collaborators
Trials By Phase
Recruitment Status
Top Conditions
Intervention Types
Top Intervention Names
Trials By Gender
Lead Sponsor
# Trials
Bayer
3
Boehringer Ingelheim
2
Clinical Trials at IPS Centro Cientifico Asistencial S.A.S
During the past decade, IPS Centro Cientifico Asistencial S.A.S conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on
average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
2022-12-05
2025-08-25
Recruiting
18,000
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "IPS Centro Cientifico Asistencial S.A.S"
#1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at IPS Centro Cientifico Asistencial S.A.S
According to Clinical.Site data, the most researched conditions in "IPS Centro Cientifico Asistencial S.A.S" are
"Heart Failure" (2 trials), "Atrial Fibrillation" (1 trials), "Chronic Heart Failure With Preserved Ejection Fraction" (1 trials), "Diabetes Mellitus, Type 2" (1 trials) and "Prevention of Stroke or Systemic Embolism" (1 trials). Many other conditions were trialed in "IPS Centro Cientifico Asistencial S.A.S" in a lesser frequency.
Clinical Trials Intervention Types at IPS Centro Cientifico Asistencial S.A.S
Most popular intervention types in "IPS Centro Cientifico Asistencial S.A.S" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (4 trials), "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials) and "Asundexian matching placebo" (1 trials). Other intervention names were less common.
Clinical Trials Genders at IPS Centro Cientifico Asistencial S.A.S
The vast majority of trials in "IPS Centro Cientifico Asistencial S.A.S" are
5 trials for "All" genders.
Clinical Trials Status at IPS Centro Cientifico Asistencial S.A.S
Currently, there are NaN active trials in "IPS Centro Cientifico Asistencial S.A.S".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 3 completed trials in IPS Centro Cientifico Asistencial S.A.S,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in IPS Centro Cientifico Asistencial S.A.S, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 3 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".